<DOC>
	<DOCNO>NCT00321217</DOCNO>
	<brief_summary>The main aim study identify genetic marker ( DNA RNA level ) involve response treatment monoclonal antibody TNF patient rheumatoid arthritis .</brief_summary>
	<brief_title>Pharmacogenomics Anti-TNF ( Anti-tumor Necrosis Factor ) Treatment Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Rheumatoid Arthritis ( RA ) severe inflammatory disease genetic factor know play important role pathogenesis . Genetic factor also involve determine prognosis RA . Identifying genetic factor predispose mild aggressive RA easy factor -like certain HLA-DR species- know . The Rheumatology department Radboud University Nijmegen Medical Centre ( RUNMC ) collect unique inception cohort 500 patient RA , follow early stage disease 10 year detailed measurement disease activity , joint damage characteristic disease progression . In project use patient group study polymorphism large battery gene effect RA disease activity/progression .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients RA accord ACR criterion treat monoclonal antiTNF antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>pharmacogenetics</keyword>
	<keyword>anti-TNF</keyword>
	<keyword>high throughput genotyping</keyword>
</DOC>